Amgen-Horizon Deal May Signal FTC’s Return To Bargaining
September 13, 2023
By: Laura C. Onken
On Sept. 1, just over a week before trial was slated to begin, the Federal Trade Commission and several states agreed to settle their challenge to Amgen Inc.'s proposed acquisition of Horizon Therapeutics, allowing the transaction to close.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IBA Annual Conference 2025
Speaking Engagement
Antitrust
GCR Live: Global Merger Control 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
In Fashion, One Day You’re In and the Next Day You’re Out (Of Chances to Plead Violations of the Sherman Act)
Axinn Viewpoints
Antitrust
Axinn Honored at the 2025 Transform Awards North America
Awards & Recognitions
Antitrust 101: Trial-Minded Antitrust Discovery
Webinar
Antitrust